Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deffered Revenue Notes Payables Operating Leases Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Organogenesis Holdings (ORGO) Current Deferred Revenue (2025)

Organogenesis Holdings has reported Current Deferred Revenue over the past 1 years, most recently at $3.9 million for Q4 2025.

For Q4 2025, Current Deferred Revenue changed N/A year-over-year to $3.9 million; the TTM value through Dec 2025 reached $3.9 million, changed N/A, while the annual FY2025 figure was $3.9 million, N/A changed from the prior year.
Current Deferred Revenue for Q4 2025 was $3.9 million at Organogenesis Holdings, up from $1.5 million in the prior quarter.
Over five years, Current Deferred Revenue peaked at $3.9 million in Q4 2025 and troughed at $1.5 million in Q3 2025.